MAIA Biotechnology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by MAIA Biotechnology, Inc. (MAIA) on March 26, 2025. The report details a corporate action regarding the company's At The Market Offering Agreement (Sales Agreement) with H.C. Wainwright & Co. LLC. MAIA is an emerging growth company incorporated in Delaware, with its principal executive offices in Chicago, IL.
Key Financial Metrics and Offering Details
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels. Instead, it focuses on capital raising activities under the Sales Agreement:
- Maximum Aggregate Offering Price: Reduced from $30,000,000 to $11,200,000.
- Shares Issued (Last 12 Months): Approximately $6,289,062 in aggregate sales price.
- Total Shares Issued (Aggregate): $11,633,086 in aggregate sales price under the Sales Agreement to date.
- Remaining Capacity: The new prospectus supplement covers an aggregate of $11,200,000.
Material Changes
The primary material change reported is the reduction of the maximum aggregate offering price available under the Sales Agreement. The company decreased the cap from $30,000,000 to $11,200,000 and filed a corresponding prospectus supplement dated March 26, 2025. This adjustment reflects the amount of shares already sold versus the original authorization.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are discussed beyond the standard legal opinion regarding the legality of the shares issuable under the Sales Agreement. The filing is strictly procedural regarding the amendment of the offering terms.
Key Facts for Investor Verification
- Verify the current market price of MAIA common stock to assess the number of shares remaining available for issuance under the new $11,200,000 cap.
- Review the full text of the prospectus supplement (dated March 26, 2025) for any updated terms or conditions of the Sales Agreement.
- Confirm the total dilution impact by comparing the $11,633,086 already raised against the company's current market capitalization.
- Check subsequent filings for any further amendments to the offering size or termination of the Sales Agreement.